Gilead to buy cancer drugmaker Immunomedics for $21 billion
Updated : September 14, 2020 10:41 AM IST
The transaction is expected to close in the fourth quarter of 2020, the companies said.
The acquisition of Immunomedics is the latest of the several Gilead inked this year with the aim of expanding its oncology portfolio.
Published : September 14, 2020 10:41 AM IST